Strategy

A Q&A with Andrew Webber, President and CEO of the National Business Coalition on Health

Pfizer's crizotinib development program combined organization, art, and science-and a large dose of unforeseen risk

The payoff is superior performance in key areas such as clinical trials

Patent expiries are inevitable, but brand teams should look to graduate the sales curve

Suggestions for testing new ways of addressing difficult issues of risk

With an emphasis on short-term objectives rather than long-term goals, pharma is missing a huge opportunity in applying market science to drive adherence

Increased efficiency and lower operating costs for both CROs and vendors can be achieved by eliminating activities

There's been much talk of how US health reform will impact physicians, patients, and insurance companies. But how will it affect the often overlooked specialty drug market?

Brand managers choosing to advertise an anti-depressant on "Criminal Minds" may not be making the best choice. New methodologies reveal "Law & Order: Special Victims Unit" along with "The Bachelor" to be shows favored by depressives

Tracking, monitoring, and trend evaluation is not enough. Companies must now do more than assess what happened and why.

Will Roche's precedent push the regulatory community to create standards that will level the playing field for all contenders?

Marketers need to understand how informal influencers are beginning to replace traditional channels as the favored way for doctors to receive product information from drug manufacturers, and, in turn, how best to leverage peer influence in designing effective meetings and events

A new leader, a big acquisition, and a bold investment in HIV may all be in the works at Gilead. But what will it take to restore the glory days?

Pfizer's VP and Assistant General Counsel for Global Patents and Policy, Roy Waldron, discusses its collaborative strategy to refresh the face of IP

When neither attitudes nor personality drive behavior, Pharma must look to social norms to understand consumer adherence issues

Scrutiny of pharmaceutical promotion and gifts to practitioners has intensified, with more states enacting reporting requirements. In May, the federal government passed the Physician Payment Sunshine Act. What kind of impact is all this having on meetings and physician attendance?

Berwick's mission: To successfully translate the new healthcare bill into practice.

It's back to the future in Pharm Exec's second-annual review of industry prospects in the IMS "Pharmerging 17"

Bonuses for reps at GlaxoSmithKline will soon be based on customer feedback and adherence to company policy, not sales targets. The move promises to transform sales & marketing, but the company offered few details about how the plan will be implemented.

John Castellani received the nod from PhRMA on Tuesday to take over the role of president and CEO in September.

As Europe sets the pace in slashing drug prices to meet austerity goals industry is seeking fresh ways to control the fallout. Will more dialogue be enough?

Outsourcing the sales representative function can help pharmaceutical companies build on their bottom line.

GSK's blockbuster diabetes drug Avandia was the subject of a number of studies this week offering good and bad news. But the company's big challenge is going to be FDA's advisory review panel set to meet in two short weeks.

Strong, skilled management is on the agenda as never before. Find out who made 2010's roster of high-potential change masters-and how they plan to lead the industry through the turbulent times ahead.

Pfizer was forced (voluntarily) to put the kibosh on a fast-tracked Wyeth drug after some not-so-favorable postmarket data. Was this a good catch or an endemic problem with expedited drugs?